You are here : HOME / NETWORK / Nicoline Hoogerbrugge

Nicoline Hoogerbrugge

Supervisor

Stichting Radboud universitair medisch centrum, NL

Nicoline Hoogerbrugge is full professor in hereditary cancer at the department of Human Genetics, Radboud university medical center Nijmegen, The Netherlands. She is chair of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) that was installed by the European Union in 2017. This network facilitates patient care, teaching, guideline development and research activities in hereditary cancer in the EU.

In her unique professional combination of being medical doctor specialized both in Internal Medicine and Cancer Genetics, she is key to the application and innovation of clinical cancer genetics that permits prevention and early detection of hereditary cancer. Her research always originates from unmet needs of hereditary cancer patients in day-to-day clinical practice. Therefore, her research has its focus in the identification as well as treatment and prevention of hereditary cancer, specifically PHTS.

Supervisors

 Ane J. Schei-Andersen (ESR3)

Publications

  • Red flags for early recognition of adult patients with PTEN Hamartoma Tumour Syndrome
    Drissen MMCM, Schieving JH, Schuurs-Hoeijmakers JHM, Vos JR, Hoogerbrugge N Eur J Med Genet. 2021 Dec;64(12):104364.
  • A review on age-related cancer risks in PTEN hamartoma tumor syndrome
    Hendricks LAJ , Hoogerbrugge N, Schuurs-Hoeijmakers JHM, Vos JR Clin Genet. 2021 Feb;99(2):219-225.
  • Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome
    Tischkowitz M, Colas C, Pouwels S, Hoogerbrugge N; PHTS Guideline Development Group; European Reference Network GENTURIS Eur J Hum Genet. 2020 Oct;28(10):1387-1393.
  • Recommendations on Surveillance for Differentiated Thyroid Carcinoma in Children with PTEN Hamartoma Tumor Syndrome
    Jonker LA, Lebbink CA, Jongmans MCJ, Nievelstein RAJ, Merks JHM, Nieveen van Dijkum EJM, Links TP, Hoogerbrugge N, van Trotsenburg ASP, van Santen HM Eur Thyroid J. 2020 Sep;9(5):234-242.
  • Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition
    CVos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N J Natl Cancer Inst. 2020 Feb 1;112(2):161-169.
  • Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome
    Sloot YJE, Rabold K, Netea MG, Smit JWA, Hoogerbrugge N, Netea-Maier RT Oncogene. 2019 May;38(19):3743-3755.
  • Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes
    Vos JR, Giepmans L, Röhl C, Geverink N, Hoogerbrugge N; ERN GENTURIS Fam Cancer. 2019 Apr;18(2):281-284.
  • PTEN Hamartoma Tumor Syndrome and Immune Dysregulation
    Eissing M, Ripken L, Schreibelt G, Westdorp H, Ligtenberg M, Netea-Maier R, Netea MG, de Vries IJM, Hoogerbrugge N Transl Oncol. 2019 Feb; 12(2): 361–367.
  • Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype
    Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RDA, Palles C, Ligtenberg MJL, Vos JR, et al Hoogerbrugge N and Kuiper R Cancer Cell. 2019 Feb 11;35(2):256-266.e5
  • High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer
    Diets I, Waanders E, Ligtenberg MJL, Bladel DV, Kamping EJ, Hoogerbrugge PM, Hopman S, Olderode-Berends MJW, Gerkes EH, Koolen D, Marcelis C, Santen GW, Belzen MV, Mordaunt D, McGregor L, Thompson E, Kattamis A, Pastorczak A, Mlynarski W, Ilencikova D, Vulto-van Silfhout A, Gardeitchik T, de Bont ESJM, Loeffen J, Wagner A, Mensenkamp AR, Kuiper RP*, Hoogerbrugge N*, Jongmans M* Clin Cancer Res. 2018 Apr 1;24(7):1594-1603.
  • Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1
    Rachel S van der Post, Ingrid P Vogelaar, Peggy Manders, Lizet E van der Kolk, Annemieke Cats, Liselotte P van Hest, Rolf Sijmons, Cora M Aalfs, Margreet G E M Ausems, Encarna B Gómez García, Anja Wagner, Frederik J Hes, Neeltje Arts, Arjen R Mensenkamp, J Han van Krieken, Nicoline Hoogerbrugge, Marjolijn J L Ligtenberg Gastroenterology. 2015 Oct;149(4):897-906.e19.
  • Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study
    Marlies J E Kempers, Roland P Kuiper, Charlotte W Ockeloen, Pierre O Chappuis, Pierre Hutter, Nils Rahner, Hans K Schackert, Verena Steinke, Elke Holinski-Feder, Monika Morak, Matthias Kloor, Reinhard Büttner, Eugene T P Verwiel, J Han van Krieken, Iris D Nagtegaal, Monique Goossens, Rachel S van der Post, Renée C Niessen, Rolf H Sijmons, Irma Kluijt, Frans B L Hogervorst, Edward M Leter, Johan J P Gille, Cora M Aalfs, Egbert J W Redeker, Frederik J Hes, Carli M J Tops, Bernadette P M van Nesselrooij, Marielle E van Gijn, Encarna B Gómez García, Diana M Eccles, David J Bunyan, Sapna Syngal, Elena M Stoffel, Julie O Culver, Melanie R Palomares, Tracy Graham, Lea Velsher, Janos Papp, Edith Oláh, Tsun L Chan, Suet Y Leung, Ad Geurts van Kessel, Lambertus A L M Kiemeney, Nicoline Hoogerbrugge, Marjolijn J L Ligtenberg Lancet Oncol. 2011 Jan;12(1):49-55.
  • Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome
    M C J Jongmans, R P Kuiper, C L Carmichael, E J Wilkins, N Dors, A Carmagnac, A Y N Schouten-van Meeteren, X Li, M Stankovic, E Kamping, H Bengtsson, E F P M Schoenmakers, A Geurts van Kessel, P M Hoogerbrugge, C N Hahn, P P Brons, H S Scott, N Hoogerbrugge Leukemia. 2010 Jan;24(1):242-6.
  • Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1
    Marjolijn J L Ligtenberg, Roland P Kuiper, Tsun Leung Chan, Monique Goossens, Konnie M Hebeda, Marsha Voorendt, Tracy Y H Lee, Danielle Bodmer, Eveline Hoenselaar, Sandra J B Hendriks-Cornelissen, Wai Yin Tsui, Chi Kwan Kong, Han G Brunner, Ad Geurts van Kessel, Siu Tsan Yuen, J Han J M van Krieken, Suet Yi Leung, Nicoline Hoogerbrugge Nat Genet. 2009 Jan;41(1):112-7.
  • Cost effectiveness of a new strategy to identify HNPCC patients
    W Kievit, J H F M de Bruin, E M M Adang, J L Severens, J H Kleibeuker, R H Sijmons, T J Ruers, F M Nagengast, H F A Vasen, J H J M van Krieken, M J L Ligtenberg, N Hoogerbrugge Gut. 2005;54:97-102.
  • High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer
    N Hoogerbrugge, P Bult, L M de Widt-Levert, L V Beex, L A Kiemeney, M J L Ligtenberg, L F Massuger, C Boetes, P Manders, H G Brunner J Clin Oncol. 2003 Jan 1;21(1):41-5.

    • Questions about PIPgen?

    Let’s talk!

    PIPgen coordinator

    Josep Carreras Leukaemia Research Institute
    Ctra de Can Ruti, Camí de les Escoles, s/n
    08916 Badalona, Spain

    PIPgen@carrerasresearch.org

    This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 955534

    Lluís Armengol Mariona Graupera